SCHEMBL1668536

SCHEMBL1668536

CS(=O)(=O)N1CCC(c2cc(F)c(OC3CN(Cc4ccc(C5(F)COC5)cc4)C3)c(F)c2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 3/20 0.35
RORC P51449 2/20 0.35
CCR3 P51677 1/20 0.35
PDE4B Q07343 1/20 0.33
DRD2 P14416 1/20 0.33
ALDH1A1 P00352 2/20 0.32
RECQL P46063 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
MGAT2 Q10469 1/20 0.32
MOGAT2 Q3SYC2 1/20 0.32
NPY5R Q15761 1/20 0.32
CYP2D6 P10635 4/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
FPR2 P25090 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12198363 0.85 S1PR1 (0.35) CACNA1HCYP3A4
SCHEMBL1668410 0.83 KDM4E (0.49) RORCCCR3ALDH1A1CYP2D6KDM4E
SCHEMBL1670849 0.80 CCR3 (0.46) RORCCCR3MEN1KMT2A
SCHEMBL1668262 0.78 KDM4E (0.48) RORCCCR3ALDH1A1CYP2D6KDM4E
SCHEMBL12198321 0.76 KDM4E (0.52) RORCDRD2ALDH1A1CYP2D6KDM4E
SCHEMBL1668617 0.75 KDM4E (0.41) RORCDRD2ALDH1A1NPY5RKDM4E
SCHEMBL1670870 0.74 MEN1 (0.42) RORCALDH1A1DPP4DPP8DPP9
SCHEMBL12198265 0.74 KDM4E (0.41) RORCPDE4BALDH1A1NPY5RCYP2D6
SCHEMBL1668975 0.74 GPR119 (0.44) ALDH1A1KMT2ACYP3A4
SCHEMBL1668510 0.74 HIF1A (0.38) ALDH1A1MOGAT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 CACNA1H 1653/4885RORC 361/4885CCR3 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.